Uniwersytecki Szpital Kliniczny
Welcome,         Profile    Billing    Logout  
 15 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Sanghoon
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Recruiting
2
18
Europe, US, RoW
HM15912 Active, Placebo
Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.
Short Bowel Syndrome
12/27
05/28
Ramlau, Rodryg
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
HLX10-020-SCLC302, NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting
3
511
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
07/25
12/26
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Suspended
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
12/24
11/25
THIO-101, NCT05208944 / 2021-005136-34: THIO Sequenced with Cemiplimab in Advanced NSCLC

Hourglass Nov 2024 - Nov 2024 : Safety and efficacy data for NSCLC
Active, not recruiting
2
182
Europe, RoW
6-Thio-2'-Deoxyguanosine, 6-thio-dG, THIO, Cemiplimab, LIBTAYO®
Maia Biotechnology, MAIA Biotechnology, Inc.
Carcinoma, Non-Small-Cell Lung
08/25
10/26
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors
Recruiting
1/2
104
Europe, US
BI-1910, Pembrolizumab
BioInvent International AB, Merck Sharp & Dohme LLC
Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
07/27
11/28
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/24
08/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT04241835: A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Recruiting
1
24
Europe, US
Tazemetostat, EPZ-6438, IPN60200, Tazverik®
Epizyme, Inc., Sponsor GmbH
Hepatic Impairment, Advanced Malignant Solid Tumor
05/25
06/25
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
N/A
50
Europe
No intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
06/27
06/27
Virchow, Isabel
KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors
Recruiting
1/2
104
Europe, US
BI-1910, Pembrolizumab
BioInvent International AB, Merck Sharp & Dohme LLC
Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
07/27
11/28

Download Options